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Abstract
Background: In a number of malaria endemic regions, tourists and travellers face a declining risk of travel
associated malaria, in part due to successful malaria control. Many millions of visitors to these regions are
recommended, via national and international policy, to use chemoprophylaxis which has a well recognized
morbidity profile. To evaluate whether current malaria chemo-prophylactic policy for travellers is cost effective
when adjusted for endemic transmission risk and duration of exposure. a framework, based on partial cost-benefit
analysis was used
Methods: Using a three component model combining a probability component, a cost component and a malaria
risk component, the study estimated health costs avoided through use of chemoprophylaxis and costs of disease
prevention (including adverse events and pre-travel advice for visits to five popular high and low malaria endemic
regions) and malaria transmission risk using imported malaria cases and numbers of travellers to malarious
countries. By calculating the minimal threshold malaria risk below which the economic costs of chemoprophylaxis
are greater than the avoided health costs we were able to identify the point at which chemoprophylaxis would be
economically rational.
Results: The threshold incidence at which malaria chemoprophylaxis policy becomes cost effective for UK
travellers is an accumulated risk of 1.13% assuming a given set of cost parameters. The period a travellers need to
remain exposed to achieve this accumulated risk varied from 30 to more than 365 days, depending on the regions
intensity of malaria transmission.
Conclusions: The cost-benefit analysis identified that chemoprophylaxis use was not a cost-effective policy for
travellers to Thailand or the Amazon region of Brazil, but was cost-effective for travel to West Africa and for those
staying longer than 45 days in India and Indonesia.
Background
Up to 37,000 European travellers acquired malaria dur-
ing 1999 [1]. In 2005, 28 million U.S. travellers visited
countries endemic for malaria and 856 cases were
reported in U.S. civilians to the National Malaria Sur-
veillance System. The risk of malaria in American tra-
vellers was calculated to vary between 137.3 per 10
5
travellers, during visits to Africa, to a risk of malaria of
0.012 per 10
5, during visits to Mexico. The risk during a
visit to South America was estimated at 2.12 per 10
5
visits [2]. Over the period 1989-99 in Europe, 680 peo-
ple died from infection with Plasmodium falciparum,
for which the use of chemoprophylaxis is highly effective
in preventing disease [1].
In the absence of a vaccine, chemoprophylaxis is the
only reliable method for preventing malaria in travellers.
Five regimens are commonly available to prevent infection:
mefloquine, doxycycline, atovaquone/proguanil, chloro-
quine, and under special circumstances, primaquine [3].
A significant number of travel-associated malaria cases
are attributable to failure to adhere to the recommended
chemoprophylaxis regimens. The proportion of UK resi-
dents who visit malaria endemic countries and use che-
moprophylaxis has been reported at around 50% [4].
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mefloquine is highly effective at preventing malaria all
drugs are known to cause adverse reactions, which
demands their prescribing to be carefully targeted [5].
Chemoprophylaxis would be recommended to indivi-
duals at risk of falciparum malaria, where the risk of
infection is higher than the risk of suffering a severe
adverse event(s) [6]. Malaria chemoprophylaxis is
selected based on an individual’s risk assessment of the
traveller, the safety and efficacy of the chemoprophylatic
regimen(s), drug resistance, and the malaria transmis-
sion intensity in the region to be visited [7]. This is
usually supported by a national recommendation using
a similar analysis. Policy ideally should contain a cost-
benefit component to supplement the above risk-
assessment.
In this paper, a framework using a partial cost-benefit
analysis was created to decide where a policy of recom-
mending malaria prophylaxis would be economically
rational. A partial cost-benefit analysis was employed as
there are incommensurable and intangible costs for
example “pain and suffering” and loss of leisure, that
cannot be easily quantified monetarily and are excluded
from the analysis.
This framework is applied to analyse the cost-effec-
tiveness of malaria chemoprophylaxis policy. The analy-
sis undertaken within this paper will not investigate the
costs and benefits from one singular perspective, such
as society or health systems view, which in the UK,
bears the costs of the treatment of malaria, or the indi-
vidual traveller, who bears both personal costs, purchas-
ing prophylaxis drugs, lost earnings when suffering
malaria and a loss of leisure cost when experiencing
adverse events from chemoprophylaxis. Rather this
paper will analyse the overall effectiveness of malaria
chemoprophylaxis policies; irrespective of the distribu-
tion of the associated costs and benefits.
The framework is adjusted for probability of malaria
transmission (malaria risk), duration of visit and cost of
providing chemoprophylaxis in the UK, and includes the
cost of adverse events and the societal costs of treat-
ment of malaria in the UK. This model allowed the cal-
culation of a threshold risk of malaria, below which the
costs of prescribing and taking chemoprophylaxis is
greater than the costs of avoided malaria. Areas with
variable transmission intensity were selected to investi-
gate the relationship of duration of exposure and risk of
malaria infection. The Amazon region of Brazil was
compared to popular tourist countries with similar
higher and lower transmission intensity.
The model
The model has three components: a probability compo-
nent; a cost component; and a malaria risk component.
Probabilities
An individual traveller to a malaria endemic area is con-
sidered to face two options either receiving or not che-
moprophylaxis. Those called ‘treated’ receive
chemoprophylaxis with a probability Pd, whereas those
called ‘un-treated’ do not receive chemoprophylaxis with
probability (1 - Pd) Treated individuals can be either
protected, with probability (efficacy of the drug) e,o r
not protected (poor compliance and breakthrough), with
probability (1 - e). Both protected and unprotected indi-
viduals can be either subject to adverse effects, with
probability Pae, or not, with probability (1 - Pae). For the
sake of generality we consider the possibility that both
treated and un-treated can acquire malaria. We denote
Pm(m | e)a n dPm(m|¯ e) the probabilities that a treated
individual gets malaria (Pm(m | e)), and the probability
that a poorly compliant treated individual gets malaria
(Pm(m|¯ e)). The complementary probabilities of not
acquiring malaria are (1 - Pm(m | e)) and (1 − Pm(m|¯ e)),
respectively. Individuals who acquire malaria can either
die of it, with probability Pt, or not, with probability (1 -
Pt). The two outcomes for an individual who does not
acquire malaria is they either die from other causes or
survive, with conditional probabilities explained below.
Un-treated individuals, in turn, can either acquire
malaria or not, with likely probabilities. In addition, un-
treated individuals can either die or not, with the corre-
spondent probabilities. The theoretical space of prob-
abilities considered is summarized in Figure 1.
Figures 1a and 1b show the conditional probabilities
for treated individuals who acquire malaria (or not)
depending on their protection status, that is, Pm(m | e)
for those whose treatment was considered effective, or
Pm(m|¯ e), for those whose treatment was considered inef-
fective. In addition, we consider that the probabilities of
dying as conditional to the fact of having malaria or not,
that is Pt(t | m)o rPt(t| ¯ m). Similarly, un-treated indivi-
duals can acquire malaria or not, with conditional prob-
abilities Pm(m | nt)a n d( 1-Pm(m | nt)), and dying or
not with the similar conditional probabilities as treated
individuals.
Costs
The costs components included in the analysis are the
cost of chemoprophylaxis, denoted Cc; the cost of devel-
oping adverse effects, denoted Cae; the cost of acquiring
malaria, denoted Cm; the cost of dying of malaria,
denoted Ct; the theoretical cost of dying of other causes
rather than malaria, denoted Co;a n dt h ec o s to fa v o i d -
ing chemoprophylaxis, denoted Cnc.
Therefore, the total cost of chemoprophylaxis has 16
components (Figure 1a), and the total cost of avoiding
chemoprophylaxis has four components (Figure 1b),
summarized in Table 1, and detailed in table 2. We
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quone/proguanil chemoprophylaxis in the model. Other
less expensive regimens could be used to explore policy
options.
Therefore, the total cost of chemoprophylaxis is the
sum of the costs S1 =
16 
i=1
Ci a n dt h et o t a lc o s to f
avoiding chemoprophylaxis is the sum of the
costsS2 =
20 
i=17
Ci, with Ci as in additional file 1.
The risk of acquiring malaria
The probability of acquiring malaria in Brazil Pm was
calculated per year from the number of imported cases
Figure 1 Probability space for the Treated (a) individual and non-treated (b)individuals.
Table 1 Costs components
Cost of Prophylaxis Cost of adverse event Cost of Malaria
Travel
1 Loss of leisure
1 Loss leisure
1
Assumed an approx. journey
cost across 3 zones in London.
The cost of the lost days of holiday
depending on severity of the reaction.
The cost of the lost days of holiday depending on severity of the reaction.
Prescription
1 Medical costs
1 Medical costs
3
Cost of Atovaquone/Proguanil
from a pharmacy.
A severe level of adverse event
requires addition medical consultation.
Cost of NHS hospitalization for malaria severity adjusted.
health costs
3 Economic & Social costs
2
Nurses consult cost. Includes days of work lost and social cost of death. The social cost of
death encapsulates the average discounted value of remaining years of life
coming solely from consumption and earnings.
Social costs
2
Work time lost to society.
1: Costs are born by the traveller
2: Costs born by society
3: Costs are born by the NHS
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made to Brazil by UK residents. We compared this prob-
ability of infection (risk) to UK travellers to India, Thai-
land, Indonesia and West Africa (Ghana, Nigeria and
Sierra Leone) identified as non-index countries The
denominator for rates was the number of UK residents
visiting the countries. This is collated from overseas tra-
vel by UK residents obtained from the Office for National
Statistics (ONS), collected as part of the International
Passenger Survey (IPS). The IPS is a year round survey of
incoming and outgoing passengers’ at all major ports.
Around 250,000 face to face interviews of a randomly
selected sample of passengers (representing 0.2% of all
travellers) provides estimates of the total annual visits
made by UK residents to other countries. The number of
imported cases was obtained from malaria surveillance
reports collected by the Malaria Reference Laboratory
(MRL) part of the Health Protection Agency (HPA). The
MRL, as the national reference laboratory, obtains
enhanced passive surveillance reports of malaria cases
through laboratories and clinicians. The risk of malaria
was estimated as the incidence per visit. The numerator
was the number of cases reported each year to the MRL.
Transmission of malaria in the five regions was
assumed to be homogeneous.. However, if seasonality is
important, this variation could be incorporated into the
model in a similar manner as used in the Brazilian
Amazon [8].
Cost-benefits analysis
Cost-benefits analysis is based on the assumption that
whenever S1 <S2 a policy supporting the use of chemo-
prophylaxis is worthwhile; and the other way around,
whenever S1 >S2 chemoprophylaxis in not cost effective
overall. In addition, there is a threshold in the risk of
acquiring malaria Pmth such that, for a given cost profile
(that is, the values assumed for the costs C1, i = 1,...,20),
that risk is greater than the threshold, chemoprophylaxis
is worthwhile. This threshold is found by making S1 =
S2.
Before proceeding with the calculation of the thresh-
old in malaria transmission intensity, it is important to
note that some of the probabilities involved in the costs
C1 (i = 1,...,20) are equal, or very close to zero, namely
Pm (m | e)a n dPt(t| ¯ m) (as a consequence, the cost of
mortality by other causes, Co is also considered zero).
This reduces the number of costs to be computed from
20 to 11. The remaining costs are C4, C8, C9, C10, C12,
C13, C14 and C16 for the treated individuals and C17, C18
and C20 for the non-treated individuals. Therefore,
Table 2 Breakdown of the monetary values
Costs considered for prescribing chemoprophylaxis include:
Travel costs £6
Prescription costs £44
2 hours off work [14] £24.48
Cost of Atovaquone/Proguanil from pharmacy £41
Nurse consult cost [15] £22.33
Adverse events and their costs are divided in three levels of severity:
Mild event
Holiday time loss (1 days) [16] £164.29
Moderate event
Holiday time loss (3 days) [16] £492.86
Severe event
Holiday time loss (7 days) [16] £1,150
Hospital costs (3 days) [15] £8,088
Illness Costs are divided into three levels of severity:
Mild Malaria
Personal costs (7 lost work days) [14] £459
Days in Hospital (3 days) [15] £8,088
Serious Malaria
Personal costs (14 lost work days) [14] £459
Days in Hospital (7 days) [15] £18,872
Death from Malaria
Social cost of death [17-19] £312,000
The social cost of death is calculated as the average discounted value of remaining years of life coming from UK consumption and
earnings. Assumed to have a 5% discount rate
Age 55 Life expectancy is 78. Average income of £27,000 therefore social cost is £312,000
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mate Pmth as:
Pmth =
 − 
 − 
(1)
where Π, Δ, Ω, and Ξ as in additional file 2.
Illustrating the model
In order to illustrate the theory above, a malaria ende-
mic area of the Amazonian region in Brazil as used. The
total number of endemic malaria cases has annually
oscillated around 600,000 over the past decade [9], of
which one quarter are P. falciparum infections [8].
This region was used to test the model and estimate
the expected risk of a traveller acquiring malaria depen-
dent on the exposure duration. We used an established
model described by Massad et al [8].
The highest probability of a traveller acquiring malaria
in the Brazilian Amazon region is during the summer
and is demonstrated as a function of the duration of
exposure in Figure 2.
The risk of acquiring all malaria (falciparum and non-
falciparum) for travellers to all the study regions and
countries, assuming that the incidence density (force of
infection) is approximately equal to the probability of
acquiring malaria (see additional file 3). Utilizing the
model [8] the relative risk of malaria for UK travellers
to each of those regions was compared to that calcu-
lated for the Amazon region of Brazil, set as equal to
one. Additional file 4 details the imported cases and the
number of UK arrivals to the regional countries.
Assuming the costs and probabilities components of
equation (1) and shown in table 3, a cost-benefit thresh-
old Pmth for malaria was Pmth = 0.011275 (1.13%).
With this as the accumulated risk, the number of days
exposure a traveller needs to remain in a region to
achieve this threshold risk was calculated and shown in
Figure 3 and Table 4.
Travellers to Brazil and Thailand never achieve the
minimal threshold whatever their duration of visit. The
higher the probability of malaria, the shorter the expo-
sure period to reach the cost-benefit threshold (thick
horizontal line).
Travel data for the countries analysed can be seen in
additional file 4.
In terms of policy on choice of chemoprophylaxis dur-
ing visits to Brazil and Thailand, it would not be cost-
effective to recommend chemoprophylaxis whatever the
Figure 2 Risk of acquiring malaria for travellers to the Brazilian Amazon region as a function of the time spent in the area. Travellers
are assumed to arrive at summer time, the season with the highest transmission (see 8)..
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in West Africa (~1 month) and is greater than 45 days
in visits to India and Indonesia.
Discussion
In this paper, the estimated cost-benefit threshold for
policy on the use of malaria chemoprophylaxis for Brit-
ish travellers visiting a variety of malaria endemic
regions was calculated. The analysis was based on avail-
able cost data, covering direct and indirect costs of
using malaria prophylaxis, incorporating for the first
time, the cost of adverse events associated with the use
of chemoprophylaxis and the health and treatment cost
associated with acquiring malaria.
If the direct and indirect costs of using chemoprophy-
laxis would fall from our models £138.00 to £15.00, the
cost-benefit threshold would fall from 1.12% to 0.044%.
The influence of the cost of the chemoprophylaxis when
reduced can have an important impact on the risk
threshold. Using alternative agents such as mefloquine
or doxycycline can change this cost component. How-
ever, this does note change the main results of our ana-
lysis (see additional file 5 for the calculations with
alternative agents). The study threshold level of 1.13% is
higher than that described by Behrens and Roberts [4],
whose cost-benefit analysis of malaria chemoprophylaxis
for travellers concluded that overall costs of preventing
malaria in travellers exceed costs of providing chemo-
prophylaxis. They argued chemoprophylaxis was cost
effective and worthwhile when the malaria incidence
was 0.7% per visit for an approximate visit of 14 days in
travellers from the UK. The authors applied similar
direct and indirect cost variables as in our model.
The travellers malaria probability is based on malaria
imported into the UK against the numerator of visits by
UK residents to five regions/countries. This malaria
Table 3 Costs and probabilities components for the
calculation ofPmth.
Cost/Prob. Value Source
Cc the cost of chemoprophylaxis £138.00
# [14]
Cae cost of adverse events £164.29
+ [14,15,17]
Cm cost of acquiring malaria £18,872.00* [15,16]
Ct cost of dying of malaria £312,000 [17]
Cnc cost of avoiding chemoprophylaxis 0 –
Pd probability of using chemoprophylaxis 0.5 [20]
Pae probability of adverse effect 0.4 [21]
Pt probabilityof dying from malaria 0.0004 [22]
e efficacy of prophylaxis 0.9 [23]
Costs are expressed in Sterling Pounds
#sum of the costs as in table 2,
+cost of mild reaction, *cost of serious malaria
(see appendix 4 for details).
Figure 3 Logarithm of the risk of acquiring malaria for travellers to 5 regions, compared with the Brazilian Amazon region. The cost-
benefit threshold is the thick horizontal line (see equation 1). Confidence intervals were omitted for the sake of clarity.
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has not been adjusted for chemoprophylaxis usage or
numbers of truly exposed travellers (regional travel), so
may not represent a true attack rate. We have also used
all species of malaria, and if Plasmodium vivax infec-
tions had been excluded, on the ground that chemopro-
phylaxis is only useful for falciparum malaria, the
difference between Africa and remainder of the regions
would have been significantly greater. For visitors to
West Africa, Behrens et al [10,11] estimated the malaria
incidence in returning travellers as 0.14%-0.26%. per
visit. For travellers to S-E Asia the incidence in Thai-
land, Cambodia and Vietnam was calculated to be <1
case per 100,000 visits (0.001% per visit) an incidence
well below (1.13%) the cost effectiveness threshold for
chemoprophylaxis policy. The model considers the risk
of acquiring malaria as a function of the duration of
exposure (visit). Using the transmission intensity esti-
mated from the probability of infection, an individual
traveller’s benefit from chemoprophylaxis could be
adjusted using the duration of exposure, taking into
account the calculated threshold
Usually cost-benefit analysis takes a perspective of one
group in the analysis. This analysis was based around
rationalising a healthy policy perspective, which included
the societal burden of the treatment of malaria, the indi-
vidual traveller, bearing the costs of purchasing prophy-
laxis, lost earnings when ill and loss of leisure when
experiencing adverse events from chemoprophylaxis.
The policy could also consider an endemic country per-
spective where reducing the requirement for chemopro-
phylaxis for visitors to the region/country makes it more
attractive to visitors and increases financial gain. It is
also feasible that such a policy based on transparent and
evidence based data may encourage travellers to accept
policy recommendation and adhere to and complete
their prescribed chemoprophylaxis regimen when it is
rationally based. This is particularly relevant when tra-
vellers can observe a policy which is influenced by dura-
tion of exposure. Policy would be more believable where
1 week and 1-year visit require different prophylaxis
regimens.
T h e s ef i n d i n g sm u s tb ei n t e r preted within the limita-
tions of the model and data quality. The model
considers only economic costs, and does not include
pain and suffering, but includes values for time lost
through both adverse events and illness from malaria.
This analysis should be considered as a methodological
proposal rather than a recipe for decision-making. The
model is very dependent on the actual incidence of tra-
vellers’ malaria to the regions and on the precision of
the cost estimates for each component of the model
The model is flexible enough to adjust for intensity of
transmission. For a different set of costs and probabil-
ities than those in Table 2, the model will allow the esti-
mated cost-benefit calculation and hence the optimal
chemoprophylaxis policy for travellers to any malarious
area. The incidence of malaria in the visited area is criti-
cal, as the cost-benefit ratio is very sensitive to changes
in the intensity of malaria transmission. Where there
are changes in transmission through seasonality, malaria
control interventions, or epidemic outbreaks this will
have a significant bearing on the model.
Growing international travel [12] and the anxiety and
concerns over the side effects of chemoprophylaxis,
which can affect up to 30% [13] of users, complicates
policy recommendations for low malaria risk regions.
The study reveals that at higher malaria probabilities (in
part due to longer exposure), the cost-benefit calculation
supports the recommendation of chemoprophylaxis.
However, where the risk of malaria acquisition varies
from region to region, a more detailed cost analysis can
lead to rational recommendations and selection of
appropriate preventative measures.
Based on the estimated incidence in UK travellers, an
average visit time of 25 days, and a set of cost para-
meters, this study suggests chemoprophylaxis policy
would not be cost-effective for UK visitors travelling to
Brazil or Thailand but would be cost-effective for visits
to West Africa and longer visits to India and Indonesia
Additional material
Additional file 1: Costs components of the model. Total costs of
chemoprophylaxis
Additional file 2: Costs components of the model. Components of
equation (1) of the main text
Additional file 3: Deduction of the probability of malaria. How the
probability of getting malaria is identified with the incidence
Table 4 Relative incidence of malaria for Brazil as compared with other countries
Region/Country Relative incidence (95% C.I.) Time in days to threshold 1.13% (95% C.I.)
Index: Brazil (Amazon) 1.0 >365
West Africa 99 (86-112) 30 (26-34)
India 5.3 (4.9-5.7) 53 (49-57)
Indonesia 6.17 (4.4-7.9) 45 (32-57)
Thailand 0.39 (0.35-0.43) >365
Duration of exposure in days each to reach the cost-benefit-risk threshold
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Page 7 of 8Additional file 4: Travel data. Travel data for the countries analysed.
Additional file 5: Model’s results with different chemoprophylaxis
agents. Duration of exposure in days each to reach the cost-benefit-risk
threshold for three different chemoprophylaxis agents
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